(Q34141323)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Nucleoside analogues and nucleobases in cancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

Carlos M Galmarini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

John R Mackey

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

415-424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Nucleoside transport and its significance for anticancer drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Metabolism and mechanisms of action of 9-(tetrahydro-2-furyl)-6-mercaptopurine in Chinese hamster ovary cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Metabolism and action of purine nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

2-Chloro-2'-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Cytosine arabinoside influx and nucleoside transport sites in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Cytarabine and neurologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily x 5-day schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Combination therapy with gemcitabine in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Biochemical modulation of arabinosylcytosine for therapy of leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900788-X

7 January 2021

10.1016/S1470-2045(02)00788-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12142171%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference